The Tubulin Colchicine Domain: a Molecular Modeling Perspective
暂无分享,去创建一个
Andrea Brancale | Alberto Massarotti | Antonio Coluccia | Giovanni Sorba | Romano Silvestri | A. Coluccia | A. Brancale | R. Silvestri | A. Massarotti | G. Sorba
[1] Carlos Alfonso,et al. Stathmin and Interfacial Microtubule Inhibitors Recognize a Naturally Curved Conformation of Tubulin Dimers* , 2010, The Journal of Biological Chemistry.
[2] G. Gordon,et al. A Phase II Study of ABT-751 in Patients with Advanced Non-small Cell Lung Cancer , 2008, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[3] A. Yamaguchi,et al. Mechanism of action of E7010, an orally active sulfonamide antitumor agent: inhibition of mitosis by binding to the colchicine site of tubulin. , 1997, Cancer research.
[4] E. Hamel,et al. Separation of active tubulin and microtubule-associated proteins by ultracentrifugation and isolation of a component causing the formation of microtubule bundles. , 1984, Biochemistry.
[5] H. Mohri. Amino-acid Composition of “Tubulin” constituting Microtubules of Sperm Flagella , 1968, Nature.
[6] Andrea Brancale,et al. New arylthioindoles: potent inhibitors of tubulin polymerization. 2. Structure-activity relationships and molecular modeling studies. , 2006, Journal of medicinal chemistry.
[7] P. Canonico,et al. Solution-phase parallel synthesis and biological evaluation of combretatriazoles. , 2008, Journal of combinatorial chemistry.
[8] T. Fojo,et al. Tubulin/microtubules: still a promising target for new chemotherapeutic agents. , 2000, Journal of the National Cancer Institute.
[9] A. Coluccia,et al. Molecular modelling studies on Arylthioindoles as potent inhibitors of tubulin polymerization. , 2011, European journal of medicinal chemistry.
[10] R. Luduena,et al. Different Effects of Vinblastine on the Polymerization of Isotypically Purified Tubulins from Bovine Brain , 2003, Investigational New Drugs.
[11] M. Carré,et al. Interaction of 4-arylcoumarin analogues of combretastatins with microtubule network of HBL100 cells and binding to tubulin. , 2006, Biochemistry.
[12] Patrick A. Curmi,et al. Insight into tubulin regulation from a complex with colchicine and a stathmin-like domain , 2004, Nature.
[13] Hai‐Liang Zhu,et al. Synthesis, biological evaluation, and molecular modeling of cinnamic acyl sulfonamide derivatives as novel antitubulin agents. , 2011, Bioorganic & medicinal chemistry.
[14] M. De Brabander,et al. The effects of methyl (5-(2-thienylcarbonyl)-1H-benzimidazol-2-yl) carbamate, (R 17934; NSC 238159), a new synthetic antitumoral drug interfering with microtubules, on mammalian cells cultured in vitro. , 1976, Cancer research.
[15] S. Monti,et al. Novel imidazole-based combretastatin A-4 analogues: evaluation of their in vitro antitumor activity and molecular modeling study of their binding to the colchicine site of tubulin. , 2006, Bioorganic & medicinal chemistry letters.
[16] F. Mollinedo,et al. Isocombretastatins A: 1,1-diarylethenes as potent inhibitors of tubulin polymerization and cytotoxic compounds. , 2009, Bioorganic & medicinal chemistry.
[17] C. Dumontet,et al. Microtubule-binding agents: a dynamic field of cancer therapeutics , 2010, Nature Reviews Drug Discovery.
[18] N. Lawrence,et al. The chemistry and biology of antimitotic chalcones and related enone systems. , 2005, Current pharmaceutical design.
[19] Kenneth H. Downing,et al. Structure of the αβ tubulin dimer by electron crystallography , 1998, Nature.
[20] D. Sackett. Podophyllotoxin, steganacin and combretastatin: natural products that bind at the colchicine site of tubulin. , 1993, Pharmacology & therapeutics.
[21] Jack A. Tuszynski,et al. Free Energy Calculations on the Binding of Colchicine and Its Derivatives with the α/β-Tubulin Isoforms , 2008, J. Chem. Inf. Model..
[22] D. Alberts,et al. Isolation and structure of the strong cell growth and tubulin inhibitor combretastatin A-4 , 1989, Experientia.
[23] T. Fojo,et al. Epothilones: a novel class of non-taxane microtubule-stabilizing agents. , 2002, Current pharmaceutical design.
[24] M. Jordan,et al. Microtubules as a target for anticancer drugs , 2004, Nature Reviews Cancer.
[25] J. Snyder,et al. Microtubule-interacting drugs for cancer treatment. , 2003, Trends in pharmacological sciences.
[26] I. Barasoain,et al. Inhibition of microtubules and cell cycle arrest by a new 1-deaza-7,8-dihydropteridine antitumor drug, CI 980, and by its chiral isomer, NSC 613863. , 1994, Cancer research.
[27] R. Ravelli,et al. Microtubule-destabilizing agents: structural and mechanistic insights from the interaction of colchicine and vinblastine with tubulin. , 2009, Topics in current chemistry.
[28] J. Tuszynski,et al. Comparative modelling of human β tubulin isotypes and implications for drug binding , 2006, Nanotechnology.
[29] L. Alphs. JANSSEN , 2012, Schizophrenia Research.
[30] J. Tuszynski,et al. Homology modeling of tubulin: influence predictions for microtubule’s biophysical properties , 2006, European Biophysics Journal.
[31] Andrew J. S. Knox,et al. Integration of ligand and structure-based virtual screening for the identification of the first dual targeting agent for heat shock protein 90 (Hsp90) and tubulin. , 2009, Journal of medicinal chemistry.
[32] Y. Engelborghs,et al. Interactions of a bicyclic analog of colchicine with beta-tubulin isoforms alphabeta(II), alphabeta(III) and alphabeta(IV). , 1997, European journal of biochemistry.
[33] Young Hoon Kim,et al. Structure-based virtual screening of novel tubulin inhibitors and their characterization as anti-mitotic agents. , 2010, Bioorganic & medicinal chemistry.
[34] Paraskevi Giannakakou,et al. Targeting microtubules for cancer chemotherapy. , 2005, Current medicinal chemistry. Anti-cancer agents.
[35] M. Jordan,et al. Effects of vinblastine, podophyllotoxin and nocodazole on mitotic spindles. Implications for the role of microtubule dynamics in mitosis. , 1992, Journal of cell science.
[36] Timothy J Mitchison,et al. Small molecules, big impact: a history of chemical inhibitors and the cytoskeleton. , 2002, Chemistry & biology.
[37] J. Jaén,et al. Selective, covalent modification of beta-tubulin residue Cys-239 by T138067, an antitumor agent with in vivo efficacy against multidrug-resistant tumors. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[38] Tudor I. Oprea,et al. Novel derivatives of 1,3,4-oxadiazoles are potent mitostatic agents featuring strong microtubule depolymerizing activity in the sea urchin embryo and cell culture assays. , 2010, European journal of medicinal chemistry.
[39] Kui Cheng,et al. Synthesis, molecular modeling and biological evaluation of dithiocarbamates as novel antitubulin agents. , 2010, Bioorganic & medicinal chemistry.
[40] L. Kotra,et al. Mechanism of action of N-phenyl-N'-(2-chloroethyl)ureas in the colchicine-binding site at the interface between alpha- and beta-tubulin. , 2009, Bioorganic & medicinal chemistry.
[41] P. Price,et al. Phase I clinical trial of weekly combretastatin A4 phosphate: clinical and pharmacokinetic results. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[42] A. Brancale,et al. Design, synthesis and structure-activity relationship of 2-(3',4',5'-trimethoxybenzoyl)-benzo[b]furan derivatives as a novel class of inhibitors of tubulin polymerization. , 2009, Bioorganic & medicinal chemistry.
[43] D. Zisterer,et al. Synthesis, evaluation and structural studies of antiproliferative tubulin-targeting azetidin-2-ones. , 2011, Bioorganic & medicinal chemistry.
[44] E. Shooter,et al. Structure of the tubulin dimer. , 1977, The Journal of biological chemistry.
[45] G. G. Stokes. "J." , 1890, The New Yale Book of Quotations.
[46] R. Luduena,et al. Kinetics of colchicine binding to purified β-tubulin isotypes from bovine brain , 1992 .
[47] Z. Deng,et al. Structural interaction fingerprint (SIFt): a novel method for analyzing three-dimensional protein-ligand binding interactions. , 2004, Journal of medicinal chemistry.
[48] Richard A. Stanton,et al. Drugs that target dynamic microtubules: A new molecular perspective , 2011, Medicinal research reviews.
[49] M. Lind,et al. Do β-tubulin mutations have a role in resistance to chemotherapy? , 2004 .
[50] B. Hill,et al. Vinflunine, the latest Vinca alkaloid in clinical development. A review of its preclinical anticancer properties. , 2001, Critical reviews in oncology/hematology.
[51] M. Steinmetz,et al. Structural basis for the regulation of tubulin by vinblastine , 2005, Nature.
[52] B. Bhattacharyya,et al. Anti‐mitotic activity of colchicine and the structural basis for its interaction with tubulin , 2008, Medicinal research reviews.
[53] N. Lawrence,et al. Tubulin as a target for anticancer drugs: Agents which interact with the mitotic spindle , 1998, Medicinal research reviews.
[54] P. Curmi,et al. The 4 Å X-Ray Structure of a Tubulin:Stathmin-like Domain Complex , 2000, Cell.
[55] J. Bryan,et al. Are cytoplasmic microtubules heteropolymers? , 1971, Proceedings of the National Academy of Sciences of the United States of America.
[56] T. Arai. Inhibition of microtubule assembly in vitro by TN‐16, a synthetic antitumor drug , 1983, FEBS letters.
[57] I. S. Johnson,et al. THE VINCA ALKALOIDS: A NEW CLASS OF ONCOLYTIC AGENTS. , 1963, Cancer research.
[58] R. Gambari,et al. Synthesis and biological evaluation of 2-amino-3-(3',4',5'-trimethoxybenzoyl)-5-aryl thiophenes as a new class of potent antitubulin agents. , 2006, Journal of medicinal chemistry.
[59] E. Taylor,et al. The colchicine-binding protein of mammalian brain and its relation to microtubules. , 1968, Biochemistry.
[60] Jonathan Y. Mane,et al. Computer assisted design of second-generation colchicine derivatives , 2010, Interdisciplinary Sciences: Computational Life Sciences.
[61] W. Figg,et al. 2‐Methoxyestradiol, a Promising Anticancer Agent , 2003, Pharmacotherapy.
[62] Ki Young Lee,et al. Design and biological evaluation of novel tubulin inhibitors as antimitotic agents using a pharmacophore binding model with tubulin. , 2006, Journal of medicinal chemistry.
[63] M. Fornabaio,et al. Docking and hydropathic scoring of polysubstituted pyrrole compounds with antitubulin activity. , 2008, Bioorganic & medicinal chemistry.
[64] Jonathan Y. Mane,et al. Quantitative analysis of the effect of tubulin isotype expression on sensitivity of cancer cell lines to a set of novel colchicine derivatives , 2010, Molecular Cancer.
[65] D. Zaharevitz,et al. A common pharmacophore for a diverse set of colchicine site inhibitors using a structure-based approach. , 2005, Journal of medicinal chemistry.
[66] Raimond B G Ravelli,et al. Variations in the colchicine-binding domain provide insight into the structural switch of tubulin , 2009, Proceedings of the National Academy of Sciences.
[67] Ping-Chiang Lyu,et al. Generation of ligand-based pharmacophore model and virtual screening for identification of novel tubulin inhibitors with potent anticancer activity. , 2009, Journal of medicinal chemistry.
[68] Weijing Sun,et al. Phase I trial of the antivascular agent combretastatin A4 phosphate on a 5-day schedule to patients with cancer: magnetic resonance imaging evidence for altered tumor blood flow. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[69] P. Vandenabeele,et al. The role of mitochondrial factors in apoptosis: a Russian roulette with more than one bullet , 2002, Cell Death and Differentiation.
[70] J. Lewin,et al. A phase I pharmacokinetic and translational study of the novel vascular targeting agent combretastatin a-4 phosphate on a single-dose intravenous schedule in patients with advanced cancer. , 2002, Cancer research.
[71] L. Wilson,et al. Mechanism of inhibition of microtubule polymerization by colchicine: inhibitory potencies of unliganded colchicine and tubulin-colchicine complexes. , 1992, Biochemistry.
[72] P. Sylvester,et al. Design and pharmacophore modeling of biaryl methyl eugenol analogs as breast cancer invasion inhibitors. , 2010, Bioorganic & Medicinal Chemistry.
[73] Giovanni Sorba,et al. Medicinal chemistry of combretastatin A4: present and future directions. , 2006, Journal of medicinal chemistry.
[74] D. Covell,et al. Mapping the binding site of colchicinoids on beta -tubulin. 2-Chloroacetyl-2-demethylthiocolchicine covalently reacts predominantly with cysteine 239 and secondarily with cysteine 354. , 2000, The Journal of biological chemistry.
[75] P. Fu,et al. A phase II trial of fosbretabulin in advanced anaplastic thyroid carcinoma and correlation of baseline serum-soluble intracellular adhesion molecule-1 with outcome. , 2009, Thyroid : official journal of the American Thyroid Association.
[76] Raimond B G Ravelli,et al. Structural insight into the inhibition of tubulin by vinca domain peptide ligands , 2008, EMBO reports.
[77] Liying Zhang,et al. Antitumor agents. 284. New desmosdumotin B analogues with bicyclic B-ring as cytotoxic and antitubulin agents. , 2011, Journal of medicinal chemistry.
[78] B. Potter,et al. Class III β-tubulin expression and in vitro resistance to microtubule targeting agents , 2009, British Journal of Cancer.
[79] F. Cabral,et al. Molecular Basis for Class V β-Tubulin Effects on Microtubule Assembly and Paclitaxel Resistance* , 2009, Journal of Biological Chemistry.
[80] F. Giles,et al. Microtubule dynamics as a target in oncology. , 2009, Cancer treatment reviews.
[81] R. Donehower,et al. Drug therapy : paclitaxel (Taxol) , 1995 .